Abstract
Fluorine is a key element in drug design due to its ability to enhance metabolic stability, binding affinity, and bioavailability. Fluorine’s properties lead to more stable drugs with longer half-lives, reducing dosing frequency and improving patient compliance. Its small size and high electronegativity also improve binding affinity, resulting in more effective treatments with lower doses. For example, fluorine increases a compound’s ability to cross cell membranes. This article highlights advancements in chiral, fluorine-containing pharmaceuticals introduced over the past five years, focusing on their synthesis, therapeutic benefits, mechanisms of action, and the impact of fluorine on efficacy and safety. Chiral molecules, essential in drug development, exist in two enantiomeric forms with distinct biological activities. Synthesizing chiral, fluorine-containing drugs involves techniques like asymmetric synthesis to produce pure enantiomers, resulting in drugs with increased potency, selectivity, and reduced side effects. Understanding their mechanisms of action provides valuable insights into efficacy and safety. Reviewing recently FDA-approved chiral drugs offers insights into fluorine chemistry in drug development and future therapeutic innovations. Recent FDA approvals highlight the significance of chiral, fluorine-containing drugs in various therapeutic areas, enabling targeted and effective treatments. Analyzing these approvals reveals trends shaping drug development’s future. The article also addresses the need for more research into self-disproportionation of enantiomers (SDE) in chiral, fluorinated compounds and concerns about excessive fluorine levels. SDE can affect pharmaceutical product purity. Research into SDE in fluorinated compounds ensures drug quality. Additionally, fluorine’s widespread use raises environmental and health concerns, necessitating studies on long-term effects and mitigation strategies.
References
Malerba F., Orsenigo L. The evolution of the pharmaceutical industry. Bus. Hist. 2015. 57(5): 664–687.
doi.org/10.1080/00076791.2014.975119.
Goodman J. Pharmaceutical industry. In Medicine in the twentieth century. Taylor & Francis. 2020. pp. 141–154. ISBN 9781003078456.
Horrobin D. F. Innovation in the pharmaceutical industry. J. Roy. Soc. Med. 2000. 93(7): 341–345.
doi.org/10.1177/014107680009300.
Cockburn I. M. The changing structure of the pharmaceutical industry. Health Affair. 2004. 23(1): 10–22.
doi.org/10.1377/hlthaff.23.1.10.
Comanor W. S. The political economy of the pharmaceutical industry. J. Econ Lit. 1986. 24(3): 1178–217.
https://www.jstor.org/stable/2725866.
Hutt A. J., Tan S. C. Drug Chirality and its Clinical Significance. Drugs. 1996. 52 (Suppl 5): 1–12.
doi.org/10.2165/00003495-199600525-00003.
Lin G. Q., You Q. D., Cheng J. F. Chiral drugs. In Chemistry and Biological Action. Wiley, 2011.
doi:10.1002/9781118075647.
Brooks W. H., Guida W. C., Daniel K. G. The significance of chirality in drug design and development. Curr. Top. Med. Chem. 2011. 11(7): 760–770.
doi: 10.2174/156802611795165098.
Ceramella J., Iacopetta D., Franchini A. et al. A look at the importance of chirality in drug activity: Some significative examples. Appl. Sci. 2022. 12(21): 10909.
doi.org/10.3390/app122110909.
Crossley R. J. Chirality and biological activity of drugs. CRC Press, 1995.
Calcaterra A., D’Acquarica I. The market of chiral drugs: Chiral switches versus de novo enantiomerically pure compounds. J. Pharmaceut. Biomed. Anal. 2018. 147: 323–340.
doi.org/10.1016/j.jpba.2017.07.008.
Wang J., Sánchez-Roselló M., Aceña J. L. et al. Fluorine in pharmaceutical industry: Fluorine-containing drugs introduced to the market in the last decade (2001–2011). Chem. Rev. 2014. 114(4): 2432–2506.
doi: 10.1021/cr4002879.
Zhou Y., Wang J., Gu Z. et al. Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas. Chem. Rev. 2016. 116(2): 422–518.
doi: 10.1021/acs.chemrev.5b00392.
Han J., Remete A. M., Dobson L. S. et al. Next generation organofluorine containing blockbuster drugs. J. Fluor. Chem. 2020. 239: 109639.
doi: 10.1016/j.jfluchem.2020.109639.
O’Hagan D. Fluorine in health care: Organofluorine containing blockbuster drugs. J. Fluor. Chem. 2010. 131(11): 1071–1081.
doi.org/10.1016/j.jfluchem.2010.03.003.
Strunecká A., Patočka J., Connett P. Fluorine in medicine. J Appl Biomed. 2004. 2: 141–150. ISSN 1214 0287.
Soloshonok V. A., Kirilenko A. G., Kukhar V. P., Resnati G. Transamination of fluorinated β-keto carboxylic esters. A biomimetic approach to β-polyfluoroalkyl-β-amino acids. TetrahedronLett. 1993. 34(22): 3621–3624.
doi: 10.1016/S0040-4039(00)73652-5.
Hagmann W. K. The many roles for fluorine in medicinal chemistry. J. Med. Chem. 2008. 51(15): 4359–4369.
doi.org/10.1021/jm800219f.
Gupta S. P. Roles of fluorine in drug design and drug action. Lett. Drug Des. Discov. 2019. 16(10): 1089–1109.
doi: 10.2174/1570180816666190130154726.
Ye Z., Zhao G. Asymmetric Synthesis of Fluorine-containing Compounds Using Organocatalysts. Chimia. 2011. 65: 902.
doi: 10.2533/chimia.2011.902.
Cahard D., Bizet V. The influence of fluorine in asymmetric catalysis. Chem. Soc. Rev. 2014. 43(1):135–147.
Bizet V., Cahard D. Fluorine as a control element in asymmetric synthesis. Chimia. 2014. 68: 378.
doi: 10.2533/chimia.2014.378.
Yamada T., Okada T., Sakaguchi K. et al.Efficient asymmetric synthesis of novel 4-substituted and configurationally stable analogues of thalidomide. Org. Lett. 2006. 8(24): 5625–5628.
doi: 10.1021/ol0623668.
Shibata N., Nishimine T., Shibata N. et al. Organic base-catalyzedstereodivergent synthesis of (R)- and (S)-3-amino-4,4,4-trifluorobutanoic acids. Chem. Commun. 2012. 48(34): 4124–4126.
doi: 10.1039/C2CC30627A.
Soloshonok V. A., Hayashi T. Gold(I)-catalyzed asymmetric aldol reaction of fluorinated benzaldehydes with α-isocyanoacetamide. Tetrahedron: Asymmetry. 1994. 5(6): 1091–1094.
doi: 10.1016/0957-4166(94)80059-6.
Ma J. A., Cahard D. Asymmetric fluorination, trifluoromethylation, and perfluoroalkylation reactions. Chem. Rev. 2004. 104(12): 6119–6146.
doi: 10.1021/cr030143e.
Soloshonok V. A., Kirilenko A. G., Fokina N. A. et al. Biocatalytic resolution of β-fluoroalkyl-β-amino acids. Tetrahedron: Asymmetry. 1994. 5(6): 1119–1126.
doi: 10.1016/0957-4166(94)80063-4.
Turcheniuk K. V., Poliashko K. O., Kukhar V. P. et al. Efficient asymmetric synthesis of trifluoromethylated β-aminophosphonates and their incorporation into dipeptides. Chem. Commun. 2012. 48(94): 11519–11521.
doi: 10.1039/C2CC36702E.
Welch J. T., Araki K., Kawecki R., Wichtowski J. A. Stereocontrol by the carbon-fluorine bond and its application to asymmetric synthesis of 3-fluoro. beta.-lactams. J. Org. Chem. 1993. 58(9): 2454–2462.
doi.org/10.1021/jo00061a019.
Zhu Y., Han J. L., Wang J.et al.Modern Approaches for Asymmetric Construction of Carbon−Fluorine Quaternary StereogenicCenters: Synthetic Challenges and Pharmaceutical Needs. Chem. Rev. 2018. 118(7): 3887−3964.
doi: 10.1021/acs.chemrev.7b00778.
Bravo P., Capelli S., Meille S. V. et al. Synthesis of optically pure (R)- and (S)-α-trifluoromethyl-alanine. Tetrahedron: Asymmetry. 1994. 5(10): 2009–2018.
doi: 10.1016/S0957-4166(00)86276-X.
Sorochinsky A. E., Aceña J. L., Soloshonok V. A. Self-disproportionation of enantiomers of chiral, non-racemic fluoroorganic compounds: Role of fluorine as enabling element. Synthesis. 2013. 45(2): 141–152.
doi: 10.1055/s-0032-1316812.
Sorochinsky A. E., Katagiri T., Ono T. et al. Optical purifications via self-disproportionation of enantiomers by achiral chromatography; Case study of a series of α-CF3-containing secondary alcohols. Chirality. 2013. 25(6): 365–368.
doi: 10.1002/chir.22180.
Soloshonok V. A., Berbasov D. O. Self-Disproportionation of Enantiomers on Achiral Phase Chromatography. One More Example of Fluorine’s Magic Powers. Chim. Oggi/ Chem. Today. 2006. 24: 44–47.
Nakamura T., Tateishi K., Tsukagoshi S. et al. Self-disproportionation of enantiomers of non-racemic chiral amine derivatives through achiral chromatography. Tetrahedron. 2012. 68(21): 4013–4017.
doi:10.1016/j.tet.2012.03.054.
Yasumoto M., Ueki H., Ono T. et al. Self-disproportionation of enantiomers of isopropyl 3,3,3-(trifluoro)lactate via sublimation:Sublimation rates vs. enantiomeric composition. J. Fluor. Chem. 2010. 131(4): 535–539.
doi.org/10.1016/j.jfluchem.2009.11.026.
Suzuki Y., Han J., Kitagawa O. et al. A comprehensive examination of the self-disproportionation of enantiomers (SDE) of chiral amides via achiral, laboratory-routine, gravity-driven column chromatography. RSC Adv. 2015. 5(4): 2988–2993.
doi: 10.1039/C4RA13928C.
Soloshonok V. A., Wzorek A., Klika K. D. A question of policy: should tests for the self-disproportionation of enantiomers (SDE) be mandatory for reports involving scalemates? Tetrahedron: Asymmetry. 2017. 28(10): 1430–1434.
doi: 10.1016/j.tetasy.2017.08.020.
Han J., Kitagawa O., Wzorek A. et al. The self-disproportionation of enantiomers (SDE): a menace or an opportunity? Chem. Sci. 2018. 9(7): 1718–1739.
doi: 10.1039/C7SC05138G.
Soloshonok V. A., Klika K. D. Terminology related to the phenomenon ‘self-disproportionation of enantiomers’ (SDE). Helv. Chem. Acta. 2014. 97(11): 1583–1589.
doi: 10.1002/hlca.201400122.
Han J., Dembinski R., Soloshonok V. A., Klika K. D. A call for a change in policy regarding the necessity for SDE tests to validate the veracity of the outcome of enantioselective syntheses, the inherent chiral state of natural products, and other cases involving enantioenriched samples. Molecules. 2021. 26(13): 3994.
doi.org/10.3390/molecules26133994.
Han J., Wzorek A., Klika K. D., Soloshonok V. A. Recommended tests for the self-disproportionation of enantiomers (SDE) to ensure accurate reporting of the stereochemical outcome of enantioselective reactions. Molecules. 2021. 26(9): 2757.
doi.org/10.3390/molecules26092757.
Han J., Kiss L., Mei H. et al. Chemical aspects of human and environmental overload with fluorine. Chem. Rev. 2021. 121(8): 4678–4742.
doi: 10.1021/acs.chemrev.0c01263.
Kabir H., Gupta A. K., Tripathy S. Fluoride and human health: Systematic appraisal of sources, exposures, metabolism, and toxicity. Crit. Rev. Env. Sci. Tec. 2020. 50(11): 1116–1193.
doi.org/10.1080/10643389.2019.1647028.
Zuo H., Chen L., Kong M. et al. Toxic effects of fluoride on organisms. Life Sci. 2018. 198: 18–24.
doi.org/10.1016/j.lfs.2018.02.001.
Ozsvath D. L. Fluoride and environmental health: a review. Rev. Env. Sci. Bio. 2009. 8:59–79.
doi: 10.1016/B978-0-444-53086-8.00012-6.
Peckham S., Awofeso N. Water Fluoridation: A Critical Review of the Physiological Effects of Ingested Fluoride as a Public Health Intervention. Sci. World J. 2014. 293019.
doi.org/10.1155/2014/293019.
Smith G. E. Fluoride, the environment, and human health. Perspect. Biol. Med. 1986. 29(4): 560–572.
doi: 10.1353/pbm.1986.0028.
Srivastava S., Flora S. J. Fluoride in Drinking Water and Skeletal Fluorosis: a Review of the Global Impact. Curr. Env. Health Rep. 2020. 7(2):140–146.
doi.org/10.1007/s40572-020-00270-9.
Mei H., Han J., Fustero S.et al. Fluorine‐Containing Drugs Approved by the FDA in 2018. Chem.—Eur. J. 2019. 25(51): 11797–11819.
doi: 10.1002/chem.201901840.
Mei H., Remete A. M., Zou Y. et al. Fluorine-containing drugs approved by the FDA in 2019. Chin. Chem. Lett. 2020. 31(9): 2401–2413.
doi: 10.1016/j.cclet.2020.03.050.
Wang Q., Bian Y., Dhawan, G. et al. FDA approved fluorine-containing drugs in 2023. Chin. Chem. Lett. 2024. 35(11): 109780.
doi: 10.1016/j.cclet.2024.109780.
Han J., Wzorek A., Dhawan G. et al. New drugs on the pharmaceutical market containing fluorine and residues of tailor-made amino acids. Ukr. Chim. J. 2024. 90(9): 31–56.
Yu Y., Liu A., Dhawan G. et al.Fluorine-containing pharmaceuticals approved by the FDA in 2020: Synthesis and biological activity. Chin. Chem. Lett. 2021. 32(11): 3342–3354.
doi: 10.1016/j.cclet.2021.05.042.
He J., Li Z., Dhawan G. et al. Fluorine-containing drugs approved by the FDA in 2021. Chin. Chem. Lett. 2023. 34(1): 107578.
doi: 10.1016/j.cclet.2022.06.001.
Wang Q., Han J., Sorochinsky A. et al. The Latest FDA-Approved Pharmaceuticals Containing Fragments of Tailor-Made Amino Acids and Fluorine. Pharmaceuticals. 2022. 15(8): 999.
doi.org/10.3390/ ph150809991847558.
Schoepfer J., Jahnke, W., Berellini G. et al., Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J. Med. Chem. 2018. 61(18): 8120–8135.
doi.org/10.1021/acs.jmedchem.8b01040.
Dhillon S., Melphalanflufenamide (Melflufen): first approval. Drugs. 2021. 81(8): 963–969.
doi.org/10.6084/m9.figshare.14390954.
Blair H. A. Sotorasib: first approval. Drugs. 2021. 81(13): 1573–1579.
doi.org/10.6084/m9.figshare.15078999.
Yin Z., Hu W., Zhang W. et al. Tailor-made amino acid-derived pharmaceuticals approved by the FDA in 2019. Amino Acids. 2020. 52(9): 1227–1261.
doi: 10.1007/s00726-020-02887-4.
Mei H., Han J., White S. et al. Tailor-made amino acids and fluorinated motifs as prominent traits in modern pharmaceuticals. Chem.—Eur. J. 2020. 26(50): 11349–11390.
doi:10.1002/chem.202000617.
Liu J., Han J., Izawa K. et al. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur. J. Med. Chem. 2020. 208: 112736.
doi: 10.1016/j.ejmech.2020.112736.
Han J., Konno H., Sato T., et al. Peptidomimetics and Peptide-Based Blockbuster Drugs. Curr. Org. Chem. 2021. 25(14):1627–1658.
doi: 10.2174/1385272825666210610155047.
Han J., Konno H., Sato T. et al.Tailor-made amino acids in the design of small-molecule blockbuster drugs. Eur. J. Med. Chem. 2021. 220: 113448.
doi: 10.1016/j.ejmech.2021.113448.
Liu A., Han J., Nakano A., et al. New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds. Chirality. 2022. 34(1): 86–103.
doi: 10.1002/chir.23376.
Wang N., Mei H., Dhawan G. et al. New Approved Drugs Appearing in the Pharmaceutical Market in 2022, Featuring Fragments of Tailor-Made Amino Acids and Fluorine. Molecules. 2023. 28(9): 3651.
doi:10.3390/molecules28093651.
Han J., Wzorek A., Dhawan G. et al.New drugs appearing on the market in 2023: molecules containing fluorine and fragments of tailor-made amino acids. Ukr. Bioorg. Acta. 2024. 19(1): 3–20.
doi: 10.15407/bioorganica2024.01.003.
Han J., Lyutenko N. V., Sorochinsky A. E., et al. Tailor-Made Amino Acids in Pharmaceutical Industry: Synthetic Approaches to Aza-Tryptophan Derivatives. Chem.—Eur. J. 2021. 27(70): 17510–17528.
doi: 10.1002/chem.202102485.
Park B. K., Kitteringham N. R., O’Neill P. M. Metabolism of fluorine-containing drugs. Ann. Rev. Pharmacol. Toxicol. 2001. 41: 443–470.
doi.org/10.1146/annurev.pharmtox.41.1.443.
Liao G. J., Clark A. S., Schubert E. K., Mankoff D. A. 18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications. J. Nucl. Med. 2016. 57(8): 1269–1275.
doi.org/10.2967/jnumed.116.175596.
Wiebe L. I. PET radiopharmaceuticals for metabolic imaging in oncology. In International Congress Series. Elsevier, 2004. 1264: 53–76.
doi.org/10.1016/j.ics.2003.12.102.
Glasspool R. M., Evans T. R. Clinical imaging of cancer metastasis. Eur. J. Cancer. 2000. 36(13): 1661–1670.
doi.org/10.1016/S0959-8049(00)00154-4.
Varagnolo L., Stokkel M. P., Mazzi U., Pauwels E. K. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG. Nucl. Med. Biol. 2000. 27(2): 103–112.
doi.org/10.1016/S0969-8051(99)00109-2.
Adam M. J., Wilbur D. S. Radiohalogens for imaging and therapy. Chem. Soc. Rev. 2005. 34(2): 153–163.
doi.org/10.1039/B313872K.
Peterson L. M., Mankoff D. A., Lawton T. et al. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol. J. Nucl. Med. 2008. 49(3): 367–374.
doi.org/10.2967/jnumed.107.047506.
Paquette M., Lavallée É., Phoenix S. et al. Improved estrogen receptor assessment by PET using the novel radiotracer 18F-4FMFES in estrogen receptor–positive breast cancer patients: an ongoing phase II clinical trial. J. Nucl. Med. 2018. 59(2): 197–203.
doi.org/10.2967/jnumed.117.194654.
Chae S. Y., Ahn S. H., Kim S. B. et al. Diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019. 20(4): 546–555.
doi: 10.1016/S1470-2045(18)30936-7.
[XX] Peterson L. M., Kurland B. F., Schubert E. K. et al. A Phase 2 Study of 16α-[18F]-fluoro-17β-estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC). Mol. Imaging Biol. 2014. 16(3): 431–440.
doi.org/10.1007/s11307-013-0699-7.
Kiesewetter D. O., Kilbourn M. R., Landvatter S. W. et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissues of immature rats. J. Nucl. Med. 1984. 25(11): 1212–1221.
Kumar P., Mercer J., Doerkson C. et al. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F] FES) in ER positive breast cancer patients. J. Pharm. Pharm. Sci. 2007. 10(2): 256s–265s.
Lim J. L., Zheng L., Berridge M. S., Tewson T. J. The use of 3-methoxymethyl-16β, 17β-epiestriol-O-cyclic sulfone as the precursor in the synthesis of F-18 16α-fluoroestradiol. Nucl. Med. Biol. 1996. 23(7): 911–915.
doi.org/10.1016/S0969-8051(96)00126-6.
Dixit M., Shi J., Wei L. et al. Synthesis of Clinical‐Grade [18F]‐Fluoroestradiol as a Surrogate PET Biomarker for the Evaluation of Estrogen Receptor‐Targeting Therapeutic Drug. Int. J. Mol. Imaging. 2013. 2013: 278607.
doi.org/10.1155/2013/278607.
Jabbour E., Issa J. P., Garcia‐Manero G., Kantarjian H. Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer: Interdis. Int. J. Am. Cancer Soc. 2008. 112(11): 2341–2351.
doi.org/10.1002/cncr.23463.
Ueda K., Masuda A., Fukuda M. et al. Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells. Drug Metab. Pharmacok. 2017. 32(6): 301–310.
doi.org/10.1016/j.dmpk.2017.10.001.
Duchmann M., Itzykson R. Clinical update on hypomethylating agents. Int. J. Hematol. 2019. 110(2): 161–169.
doi.org/10.1007/s12185-019-02651-9.
Belyakov S., Hamilton G. S., Duvall B. et al. AU2016213880B2, 2016.
Camiener G. W. Studies of the enzymatic deamination of cytosine arabinoside—III: Substrate requirements and inhibitors of the deaminase of human liver. Biochem. Pharmacol. 1967. 16(9): 1691–1702.
doi.org/10.1016/0006-2952(67)90244-4.
Hosono H., Kuno S. The purification and properties of cytidine deaminase from Escherichia coli. J. Biochem. 1973. 74(4): 797–803.
doi.org/10.1093/oxfordjournals.jbchem.a130 305.
Teh A. H., Kimura M., Yamamoto M. et al. The 1.48 Å resolution crystal structure of the homotetrameric cytidine deaminase from mouse. Biochemistry. 2006. 45(25): 7825–7833.
doi.org/10.1021/bi060345f.
Costanzi S., Vilar S., Micozzi D. et al. Delineation of the molecular mechanisms of nucleoside recognition by cytidine deaminase through virtual screening. ChemMedChem. 2011. 6(8): 1452–1458.
doi.org/10.1002/cmdc.201100139.
Ferraris D., Duvall B., Delahanty G. et al. Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine
derivatives as inhibitors of cytidine deaminase. J. Med. Chem. 2014. 57(6): 2582–2588.
doi.org/10.1021/jm401856k.
Oganesian A., Redkar S., Taverna P. Preclinical data in cynomolgus (cyn) monkeys of ASTX727, a novel oral hypomethylating agent (HMA) composed of low-dose oral decitabine combined with a novel cytidine deaminase inhibitor (CDAi). Blood. 2013. 122(21): 2526.
doi.org/10.1182/blood.V122.21.2526.2526.
Savona M. R., Odenike O., Amrein P. C. et al. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Lancet Haematol. 2019. 6(4): e194–e203.
doi: 10.1016/S2352-3026(19)30030-4.
Garcia-Manero G., Griffiths E. A., Steensma D. P. et al. Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study. Blood. 2020. 136(6): 674–683.
doi.org/10.1182/blood.2019004143.
Dhillon S. Decitabine/cedazuridine: first approval. Drugs. 2020. 80(13): 1373–1378.
doi.org/10.1007/s40265-020-01389-7.
Norton J., Matsuo H., Sturla S. J. Synthesis of deoxytetrahydrouridine. J. Org. Chem. 2009. 74(5): 2221–2223.
doi.org/10.1021/jo802599v.
Deeks E. D. Belzutifan: first approval. Drugs. 2021. 81(16): 1921–1927.
doi.org/10.1007/s40265-021-01606-x.
Choueiri T. K., Bauer T. M., Papadopoulos K. P. et al. Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat. Med. 2021. 27(5): 802–805.
doi.org/10.1038/s41591-021-01324-7.
Jaakkola P., Mole D. R., Tian Y.-M. et al. Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. Science. 2001. 292(5516): 468–472.
doi: 10.1126/science.105979.
Bruick R. K., McKnight S. L. A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF. Science. 2001. 294(5545): 1337–1340.
doi: 10.1126/science.1066373.
Scheuermann T. H., Tomchick D. R., Machius M. et al. Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proc. Natl. Acad. Sci
U. S. A. 2009. 106(2): 450–455.
doi.org/10.1073/pnas.0808092106.
Scheuermann T. H., Li Q., Ma H. W. et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat. Chem. Biol. 2013. 9(4): 271–276.
doi.org/10.1038/nchembio.1185.
Rogers J. L., Bayeh L., Scheuermann T. H., et al. Development of Inhibitors of the PAS-B Domain of the HIF-2α Transcription Factor. J. Med. Chem. 2013. 56(4): 1739–1747.
doi.org/10.1021/jm301847z.
Scheuermann T. H., Stroud D., Sleet C. E. et al. Isoform-Selective and Stereoselective Inhibition of Hypoxia Inducible Factor-2. J. Med. Chem. 2015. 58(15): 5930–5941.
doi.org/10.1021/acs.jmedchem.5b00529.
Wehn P. M., Rizzi J. P., Dixon D. D. et al. Design and Activity of SpecificHypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear CellRenalCellCarcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J. Med. Chem. 2018. 61(21): 9691–9721.
doi.org/10.1021/acs.jmedchem.8b01196.
Wallace E. M., Rizzi J. P., Han G. et al. A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma. Cancer Res. 2016. 76(18): 5491–5500.
doi.org/10.1158/0008-5472.CAN-16-0473.
Cho H., Du X., Rizzi J. P. et al. On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature. 2016. 539(7627): 107–111.
doi.org/10.1038/nature19795.
Chen W., Hill H., Christie A. et al. Targeting renal cell carcinoma with a HIF-2 antagonist. Nature. 2016. 539(7627): 112–117.
doi.org/10.1038/nature19796.
Xu R., Wang K., Rizzi J. P. et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl] oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J. Med. Chem. 2019. 62(15): 6876–6893.
doi.org/10.1021/acs.jmedchem.9b00719.
Choueiri T. K., Motzer R. J. Systemic therapy for metastatic renal-cell carcinoma. New Eng. J. Med. 2017. 376(4): 354–366.
doi: 10.1056/NEJMra1601333.
Josey J. A., Shrimali R., Wallace E. M., Wong T. WO 2019191227, 2019.
Louis D. N., Perry A., Wesseling P. et al.The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro-oncology. 2021. 23(8): 1231–1251. doi.org/10.1093/neuonc/noab106.
Schaff L. R., Mellinghoff I. K. Glioblastoma and other primary brain malignancies in adults: a review. JAMA. 2023. 329(7): 574–587.
doi:10.1001/jama.2023.0023.
Parsons D. W., Jones S., Zhang X. et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008. 321(5897): 1807–1812.
doi: 10.1126/science.1164382.
Yan H., Parsons D. W., Jin G. et al. IDH1 and IDH2 mutations in gliomas. New Eng. J. Med. 2009. 360(8): 765–773.
doi: 10.1056/NEJMoa0808710.
Hartmann C., Meyer J., Balss J. et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. ActaNeuropathol. 2009. 118: 469–474.
doi.org/10.1007/s00401-009-0561-9.
Solomou G., Finch A., Asghar A. et al. Mutant IDH in gliomas: Role in cancer and treatment options. Cancers. 2023. 15(11): 2883. doi.org/10.3390/cancers15112883.
Lu C., Ward P. S., Kapoor G. S. et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012. 483(7390): 474–478.
doi.org/10.1038/nature10860.
Xu W., Yang H., Liu Y. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011. 19(1): 17–30.
doi: 10.1016/j.ccr.2010.12.014.
Cancer Genome Atlas Research Network, Brat D. J., Verhaak R. G., Aldape K. D. et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. New Engl. J. Med. 2015. 372(26): 2481–2498.
doi: 10.1056/NEJMoa1402121.
Eckel-Passow J. E., Lachance D. H., Molinaro A. M. et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. New Eng. J. Med. 2015. 372(26): 2499–2508.
doi: 10.1056/NEJMoa1407279.
Mandonnet E., Delattre J. Y., Tanguy M. L. et al. Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann. Neurol. 2003. 53(4): 524–528.
doi.org/10.1002/ana.10528.
Rees J., Watt H., Jäger H. R. et al. Volumes and growth rates of untreated adult low-grade gliomas indicate risk of early malignant transformation. Eur. J. Radiol. 2009. 72(1): 54–64.
doi.org/10.1016/j.ejrad.2008.06.013.
Lamb Y. N. Vorasidenib: First Approval. Drugs. 2024. 84(10): 1325–1331.
doi.org/10.1007/s40265-024-02097-2.
Liu S., Abboud M., Mikhailov V. et al. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors. J. Med. Chem. 2023. 66(7): 5279–5288.
doi.org/10.1021/acs.jmedchem.3c00203.
Popovici-Muller J., Lemieux R. M., Artin E. et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 2018. 9(4): 300–305.
doi.org/10.1021/acsmedchemlett.7b00421.
Yen K., Travins J., Wang F. et al. AG-221, a first-in-class therapy targeting acute myeloid leukemiaharboring oncogenic IDH2 mutations. Cancer Discov. 2017. 7(5): 478–493. doi.org/10.1158/2159-8290.CD-16-1034.
Mellinghoff I. K., Van Den Bent M. J., Blumenthal D. T. et al. Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Gglioma. New Eng. J. Med. 2023. 389(7): 589–601.
doi: 10.1056/NEJMoa2304194.
Dang L., White D. W., Gross S. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009. 462(7274): 739–744.
doi.org/10.1038/nature08617.
Ward P. S., Patel J., Wise D. R. et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010. 17(3): 225–234.
doi: 10.1016/j.ccr.2010.01.020.
Mellinghoff I. K., Penas-Prado M., Peters K. B. et al. Vorasidenib, a dual inhibitor of mutant IDH1/2, in recurrent or progressive glioma; results of a first-in-human phase I trial. Clin. Cancer Res. 2021. 27(16): 4491–4499.
doi.org/10.1158/1078-0432.CCR-21-0611.
Rudà R., Horbinski C., van den Bent M. et al. IDH inhibition in gliomas: from preclinicalmodels to clinical trials. Nat. Rev. Neurol. 2024. 20(7): 395–407.
doi: 10.1038/s41582-024-00967-7.
Bombino A., Magnani M., Conti A. A Promising Breakthrough: The Potential of VORASIDENIB in the Treatment of Low-grade Glioma. Curr. Mol. Pharmacol. 2024. 17(1): e18761429290327.
doi.org/10.2174/0118761429290327240222061812.
Konteatis Z. D., Popovici-Muller J., Travins J. M. et al. PT WO 2015003640 A1, 2015.
Moore J. L., Taylor S. M., Soloshonok V. A. An efficient and operationally convenient general synthesis of tertiary amines by direct alkylation of secondary amines with alkyl halides in the presence of Huenig’s base. Arkivoc. 2005. 2005(vi): 287–292.
doi.org/10.3998/ark.5550190.0006.624.
Soloshonok V. A., Ono T. The effect of substituents on the feasibility of azomethine-azomethine isomerization: new synthetic opportunities for biomimetic transamination. Tetrahedron. 1996. 52(47): 14701–14712.
doi.org/10.1016/0040-4020(96)00920-9.
Ohkura H., Berbasov D. O., Soloshonok V. A. Chemo-and regioselectivity in the reactions between highly electrophilic fluorine containing dicarbonyl compounds and amines. Improved synthesis of the corresponding imines/enamines. Tetrahedron. 2003. 59(10): 1647–1656.
doi.org/10.1016/S0040-4020(03)00138-8.
Soloshonok V. A., Kirilenko A. G., Kukhar V. P., Resnati G. Transamination of fluorinated β-keto carboxylic esters. A biomimetic approach to β-polyfluoroalkyl-β-amino acids. Tetrahedron Lett. 1993. 34(22): 3621–3624.
doi.org/10.1016/S0040-4039(00)73652-5.
Soloshonok V. A., Kirilenko A. G., Fokina N. A. et al. Chemo-enzymatic approach to the synthesis of each of the four isomers of α-alkyl-β-fluoroalkyl-substituted β-amino acids. Tetrahedron: Asymmetry. 1994. 5(7): 1225–1228.
doi.org/10.1016/0957-4166(94)80163-0.
Soloshonok V. A., Kirilenko A. G., Galushko S. V., Kukhar V. P. Catalytic asymmetric synthesis of β-fluoroalkyl-β-amino acids via biomimetic [1,3]-proton shift reaction. TetrahedronLett. 1994. 35(28): 5063–5064.
doi: 10.1016/S0040-4039(00)73320-X.
Soloshonok V. A., Ono T., Soloshonok I. V. Enantioselective biomimetic transamination of β-keto carboxylic acid derivatives. An efficient asymmetric synthesis of β-fluoroalkyl β-amino acids. J. Org.Chem. 1997. 62(22): 7538–7539.
doi: 10.1021/jo9710238.
Soloshonok V. A., Kukhar V. P. Biomimetic transamination of α-ketoperfluorocarboxylic esters. An efficient preparative synthesis of β,β,β-trifluoroalanine. Tetrahedron. 1997. 53(25): 8307–8314.
doi: 10.1016/S0040-4020(97)00517-6.
Hoy S. M. Oteseconazole: First Approval. Drugs. 2022. 82: 1017–1023.
doi: 10.6084/m9.figshare.19896604.
Warrilow A. G., Hull C. M., Parker J. E. et al. The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme. Antimicrob. Agents Chemother. 2014. 58(12): 7121–7127.
doi.org/10.1128/aac.03707-14.
Garvey E. P., Hoekstra W. J., Moore W. R. et al. VT-1161 dosed once daily or once weekly exhibits potent efficacy in treatment of dermatophytosis in a guinea pig model. Antimicrob. Agents Chemother. 2015. 59(4): 1992–1997.
doi.org/10.1128/aac.04902-14.
Martens M. G., Maximos B., Degenhardt T. et al. Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections. Am. J. Obstet. Gynecol. 2022. 227(6): 880-e1.
doi.org/10.1016/j.ajog.2022.07.023.
Hoekstra W. J., Garvey E. P., Moore W. R. et al. Design and optimization of highly-selective fungal CYP51 inhibitors. Bioorg. Med. Chem. Lett. 2014. 24(15): 3455–3458.
doi.org/10.1016/j.bmcl.2014.05.068.
Hoekstra W. J., Yates C. M. Antifungal compound process. WO 2015143142 A1, 2015.
Ali I., Alam S. D., Al-Othman Z. A., Farooqi J. A. Recent advances in SPE–chiral-HPLC methods for enantiomeric separation of chiral drugs in biological samples. J. Chromatogr. Sci. 2013. 51(7): 645–654.
doi.org/10.1093/chromsci/bms262.
Marek W. K., Lee J. W., Seidel-Morgenstern A., Antos D. Separation of nonracemic mixtures of enantiomers by achiral simulated moving bed chromatography. Sep. Purif. Technol. 2025. 361(3): 131497.
doi.org/10.1016/j.seppur.2025.131497.
Yasumoto M., Ueki H., Soloshonok V. A. Self-disproportionation of enantiomers of 3,3,3-trifluorolactic acid amides via sublimation. J. Fluor. Chem. 2010. 131(2): 266–269.
doi.org/10.1016/j.jfluchem.2009.10.002.
Han J., Wzorek A., Kwiatkowska M. et al. The self-disproportionation of enantiomers (SDE) of amino acids and their derivatives. Amino Acids. 2019. 51(6): 865–889.
doi.org/10.1007/s00726-019-02729-y.
Wzorek A., Klika K. D., Drabowicz J. et al. The self-disproportionation of the enantiomers (SDE) of methyl n-pentyl sulfoxide via achiral, gravity-driven column chromatography: a case study. Org. Biomol. Chem. 2014. 12(26): 4738–4746.
doi: 10.1039/c4ob00831f.
Segal-Maurer S., DeJesus E., Stellbrink H. J. et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. New Eng. J. Med. 2022. 386(19): 1793–1803.
doi: 10.1056/NEJ Moa2115542.
Thenin-Houssier S., Valente S. HIV-1 capsid inhibitors as antiretroviral agents. Curr. HIV Res. 2016. 14(3): 270–282.
doi: 10.2174/1570162x14999160224103555.
Carnes S. K., Sheehan J. H., Aiken C. Inhibitors of the HIV-1 capsid, a target of opportunity. Curr. Opin. HIV AIDS. 2018. 13(4): 359–365.
doi: 10.1097/COH.0000000000000472.
Scott D. E., Bayly A. R., Abell C., Skidmore J. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge. Nat. Rev. Drug Discov. 2016. 15(8): 533–550.
doi.org/10.1038/nrd.2016.29.
Freed E. O. HIV-1 assembly, release and maturation. Nat. Rev. Microbiol. 2015. 13(8): 484–496. doi.org/10.1038/nrmicro3490.
Ganser B. K., Li S., Klishko V. Y. et al. Assembly and analysis of conical models for the HIV-1 core. Science. 1999. 283(5398): 80–83.
doi: 10.1126/science.283.5398.
Yamashita M., Engelman A. N. Capsid-dependent host factors in HIV-1 infection. Trends Microbiol. 2017. 25(9): 741–755.
doi: 10.1016/j.tim.2017.04.004.
Huang P. T., Sum mers B. J., Xu C. et al. FEZ1 is recruited to a conserved cofactor site on capsid to promote HIV-1 trafficking. Cell Rep. 2019. 28(9): 2373–2385.
doi: 10.1016/j.celrep.2019.07.079.
Fernandez J., Machado A. K., Lyonnais S. et al. Transportin-1 binds to the HIV-1 capsid via a nuclear localization signal and triggers uncoating. Nat. Microbiol. 2019. 4(11): 1840–1850.
doi.org/10.1038/s41564-019-0575-6.
US Food and Drug Administration. FDA approves new HIV drug for adults with limited treatment options. 2023.
Zhou L., Sokolskaja E., Jolly C. et al. Transportin 3 promotes a nuclear maturation step required for efficient HIV-1 integration. PLoSPathog. 2011. 7(8): e1002194.
doi.org/10.1371/journal.ppat.1002194.
Link J. O., Rhee M. S., Tse W. C. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020. 584(7822): 614–618.
doi.org/10.1038/s41586-020-2443-1.
Bester S. M., Wei G., Zhao H. et al. Structural and mechanistic bases for a potent HIV-1
capsid inhibitor. Science. 2020. 370(6514): 360–364.
doi: 10.1126/science.abb4808.
Singh K., Gallazzi F., Hill K. J. GS-CA Compounds: First-In-Class HIV-1 Capsid Inhibitors Covering Multiple Grounds. Front. Microbiol. 2019. 10: 1227.
doi.org/10.3389/fmicb.2019.01227.
Margot N., Ram R., Rhee M., Callebaut C. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes. Antimicrob. Agents Chemother. 2021. 65(3): 10–128.
doi.org/10.1128/aac.02057-20.
Bekerman E., Blari W. S., Chiu A. et al. Capsid inhibitors for prevention of HIV. US2021188815A1, 2021.
Ellman J. A. Applications of tert-butanesulfinamide in the asymmetric synthesis of amines. Pure App. Chem. 2003. 75(1): 39–46.
doi.org/10.1351/pac200375010039.
Robak M. T., Herbage M. A., Ellman J. A. Synthesis and Applications of tert-Butanesulfinamide. Chem. Rev. 2010. 110(6): 3600–3740.
doi.org/10.1021/cr900382t.
Xie C., Wu L., Mei H. et al. Generalized access to fluorinated β-keto amino compounds through asymmetric additions of α,α-difluoroenolates to CF3-sulfinylimine. Org. Biomol. Chem. 2014. 12(39): 7836–7843.
doi: 10.1039/C4OB01575D.
Xie C., Dai, Y., Mei H. et al. Asymmetric synthesis of quaternary α-fluoro-β-keto-amines viadetrifluoroacetylativeMannich reactions. Chem. Commun. 2015. 51(44): 9149–9152.
doi: 10.1039/c5cc02256h.
Drug Trials Snapshots: VOYDEYA. Available at https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-voydeya.
Hao J., Milcent T., Retailleau P. et al. Asymmetric Synthesis of Cyclic Fluorinated Amino Acids. Eur. J. Org. Chem. 2018. 2018(27–28): 3688–3692.
doi: 10.1002/ejoc.201800255.
Sato T., Izaw K., Aceña J. L. et al. Tailor-Madeα-Amino Acids in thePharmaceuticalIndustry: SyntheticApproachesto (1R,2S)-1-Amino-2-vinylcyclopropane-1-carboxylic A cid (Vinyl-ACCA). Eur. J. Org. Chem. 2016. 2016(16): 2757–2774.
doi: 10.1002/ejoc.201600112.
Cai C., Soloshonok V. A., Hruby V. J. Michael Addition Reactions Between Chiral Ni(II) Complex of Glycine and 3-(trans-Enoyl)oxazolidin-2-ones. A Case of Electron Donor−Acceptor Attractive Interaction-Controlled Face Diastereoselectivity. J. Org. Chem. 2001. 66(4): 1339–1350.
doi: 10.1021/jo0014865.
Soloshonok V. A., Ueki H., Tiwari R. et al. Virtually Complete Control of Simple and Face Diastereoselectivity in the Michael Addition Reactions between Achiral Equivalents of a Nucleophilic Glycine and (S)- or (R)-3-(E-Enoyl)-4-phenyl-1,3-oxazolidin-2-ones: Practical Method for Preparation of β-Substituted Pyroglutamic Acids and Prolines. J. Org. Chem. 2004. 69(15): 4984–4990.
doi: 10.1021/jo0495438.
Soloshonok V. A., Ueki H., Ellis T. K. et al. Application of modular nucleophilic glycine equivalents for truly practical asymmetric synthesis of β-substituted pyroglutamic acids. Tetrahedron Lett. 2005. 46(7): 1107–1110.
doi: 10.1016/j.tetlet.2004.12.093.
Wiles J. A., Phadke A. S., Deshpande M. et al. Achillion Pharmaceuticals Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders. U.S. Patent Application 2018305375 A1, 2018.
Wiles J. A., Phadke A. S., Deshpande M., Agarwal A., Chen D., Gadhachanda V. R., Hashimoto A., Pais G., Wang Q., Wang X. Achillion Pharmaceuticals Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders. U.S. Patent 10822352 B2, 2020.
Kang C. Danicopan: First Approval. Drugs. 2024. 84(5): 613–618.
doi:10.1007/s40265-024-02023-6.
Verdin P. FDA new drug approvals in Q1 2024. Nat. Rev. Drug Discov. 2024. 23(5): 331.
doi:10.1038/d41573-024-00063-x.
Kulasekararaj A. G., Lazana I. Paroxysmal nocturnal hemoglobinuria: Where are we going. Am. J. Hematol. 2023. 98(S5): S33–S43.
doi:10.1002/ajh.26882.
Voydeya (Danicopan) granted first-ever regulatory approval in Japan for adults with PNH to be used in combination with C5 inhibitor therapy. Available at https://www.astrazeneca.com./media-centre/press-releases/2024/voydeya-danicopan-granted-first-ever-regulatory-approval-in-japan-for-adults-with-pnh-to-be-used-in-combination-with-c5-inhibitor-therapy.html.
First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria. Available at https://www.ema.europa.eu/en/news/
first-oral-treatment-against-residual-haemolytic-anaemia-patients-paroxysmal-nocturnal-haemoglobinuria.
Wiles J. A., Phadke A. S., Deshpande M. et al. Achillion Pharmaceuticals Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders. WO 2017035353A1, 2017.
Phadke A., Hashimoto A., Andres M., Achillion Pharmaceuticals Inc. Morphic forms of complement factor D inhibitors. WO 2020069024A1, 2020.
Phadke A. Achillion Pharmaceuticals Inc. Morphic forms of complement factor D inhibitors. WO 2020051538A1, 2020.
Aslan B., Kismali G., Iles L. R. et al. Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. BloodCancer J. 2022. 12(5): 80.
doi.org/10.1038/s41408-022-00675-9.
Gomez E. B., Ebata K., Randeria H. S. et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023. 142(1): 62–72.
doi.org/10.1182/blood.2022018674.
Thompson P. A., Tam C. S. Pirtobrutinib: a new hope for patients with BTK inhibitor–refractory lymphoproliferative disorders. Blood. 2023. 141(26): 3137–3142.
doi.org/10.1182/blood.2023020240.
Telaraja D., Kasamon Y. L., Collazo J. S. et al. FDA approval summary: pirtobrutinib for relapsed or refractory mantle cell lymphoma. Clin. Cancer Res. 2024. 30(1): 17–22.
doi.org/10.1158/1078-0432.CCR-23-1272.
Keam S. J. Pirtobrutinib: First Aapproval. Drugs. 2023. 83(6): 547–553.
doi.org/10.1007/s40265-023-01860-1.
Arguelles D., Alonso J., Eary C. T. et al. PT WO 2022056100 A1, 2022.
Guisot N. PT US 2021093611 A1, 2021.
Turner N. C., Im S.-A., Saura C. et al. Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. New Engl. J. Med. 2024. 391(17): 1584–1596.
doi: 10.1056/NEJMoa2404625.
Bartsch R. Next generation of drugs in breast cancer. memo – Mag. Eur. Med. Oncol. 2024. 17(4): 280–286.
doi: 10.1007/s12254-024-00999-1.
Singh S., Bradford D., Li X. et al. FDA approval summary: Alpelisib for PIK3CA-related overgrowth spectrum. Clin. Cancer Res. 2024. 30(1): 23–28.
doi: 10.1158/1078-0432.CCR-23-1270.
Sirico M., D’Angelo A., Gianni C. et al. Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy. Cancers. 2023. 15(3): 703.
doi: 10.3390/cancers15030703.
Salphati L., Pang J., Plise E. G. et al. Preclinical assessment of the PI3Kα selective inhibitor inavolisib and prediction of its pharmacokinetics and efficacious dose in human. Xenobiotica. 2024. 54(10): 808–820.
doi: 10.1080/00498254.2024.2415103.
Shan K. S., Bonano-Rios A., Theik N. W. Y. et al. Molecular targeting of the phosphoinositide-3-protein kinase (PI3K) pathway across various cancers. Int. J. Mol. Sci. 2024. 25(4): 1973.
doi: 10.3390/ijms25041973.
Belli C., Repetto M., Anand S. et al. The emerging role of PI3K inhibitors for solid tumour treatment and beyond. Br. J. Cancer. 2023. 128(12): 2150–2162.
doi: 10.1038/s41416-023-02221-1.
Yu M., Chen J., Xu Z. et al. Development and safety of PI3K inhibitors in cancer. Arch. Toxicol. 2023. 97(3): 635–650.
doi: 10.1007/s00204-023-03440-4.
Vanhaesebroeck B., Perry M. W. D., Brown J. R. et al. PI3K inhibitors are finally coming of age. Nat. Rev. Drug Discov. 2021. 20(10): 741–769.
doi: 10.1038/s41573-021-00209-1.
Song K. W., Edgar K. A., Hanan E. J. et al. RTK-dependent inducible degradation of mutant PI3Kα drives GDC-0077 (Inavolisib) efficacy. Cancer Discov. 2022. 12(1): 204–219.
doi: 10.1158/2159-8290.CD-21-0072.
Hanan E. J., Braun M.-G., Heald R. A. et al. Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα. J. Med. Chem. 2022. 65(24): 16589–16621.
doi: 10.1021/acs.jmedchem.2c01422.
Lovering F., Bikker J., Humblet C. Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success. J. Med. Chem. 2009. 52(21): 6752–6756.
doi.org/10.1021/jm901241e.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2025 Jianlin Han, Alicja Wzorek, Gagan Dhawan, Wei Zhang, Alexander Sorochinsky, Daniel Baecker, Taizo Ono, Karel Klika, Vadim Soloshonok